Weekly Analysts’ Ratings Updates for GlaxoSmithKline (GSK)

GlaxoSmithKline (NYSE: GSK) has recently received a number of price target changes and ratings updates:

  • 2/9/2018 – GlaxoSmithKline was upgraded by analysts at Kepler Capital Markets from a “reduce” rating to a “hold” rating.
  • 2/7/2018 – GlaxoSmithKline was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating.
  • 2/5/2018 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 2/2/2018 – GlaxoSmithKline was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 1/29/2018 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 1/17/2018 – GlaxoSmithKline was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaxo enjoys a diversified base and presence in different geographical areas. Glaxo should continue to see strong performance in its Pharmaceuticals and Vaccines business units. We are positive on the company’s efforts to develop its pipeline. We think Glaxo possesses one of the stronger late-stage pipelines in large-cap pharma. Performance of new products has been encouraging. Meanwhile, back-to-back approvals of three new products – Trelegy Ellipta, Shingrix and Jucalla – have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company’s performance. The slowdown in sales of the Consumer Healthcare segment in 2017 is also a concern. Estimates have declined slightly ahead of Q4 earnings release. However, Glaxo has a positive record of earnings surprises in recent quarters.”
  • 1/16/2018 – GlaxoSmithKline was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating.
  • 1/15/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at UBS Group AG.
  • 1/11/2018 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 1/10/2018 – GlaxoSmithKline was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaxo enjoys a diversified base and presence in different geographical areas. Glaxo should continue to see strong performance in its Pharmaceuticals and Vaccines business units. We are positive on the company’s efforts to develop its pipeline. We think Glaxo possesses one of the stronger late-stage pipelines in large-cap pharma. Performance of new products has been encouraging. Meanwhile, back-to-back approvals of three new products – Trelegy Ellipta, Shingrix and Jucalla – have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company’s performance. The slowdown in sales of the Consumer Healthcare segment in 2017 is also a concern. Estimates have declined slightly ahead of Q4 earnings release. However, Glaxo has a positive record of earnings surprises in recent quarters.”
  • 1/9/2018 – GlaxoSmithKline was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $42.00 price target on the stock. According to Zacks, “Glaxo enjoys a diversified base and presence in different geographical areas. Glaxo should continue to see strong performance in its Pharmaceuticals and Vaccines business units. We are positive on the company’s efforts to develop its pipeline. We think Glaxo possesses one of the stronger late-stage pipelines in large-cap pharma. Performance of new products has been encouraging. Meanwhile, back-to-back approvals of three new products – Trelegy Ellipta, Shingrix and Jucalla – have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company’s performance. The slowdown in sales of the Consumer Healthcare segment this year is also a concern. Estimates have declined slightly ahead of Q4 earnings release. However, Glaxo has a positive record of earnings surprises in recent quarters.”
  • 1/4/2018 – GlaxoSmithKline was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “We are positive on Glaxo’s efforts to develop its pipeline. Performance of new products has been encouraging. Meanwhile, back-to-back approvals of three new products – Trelegy Ellipta, Shingrix and Jucalla – have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company’s performance. Meanwhile, its top-selling respiratory product, Advair is also expected to face generic competition in the United States next year, which will further hurt sales. The slowdown in sales of the Consumer Healthcare segment this year is also a concern. Glaxo’s shares underperformed the broader industry in 2017. However, estimates have gone up slightly ahead of Q4 earnings release. The company has a positive record of earnings surprises in recent quarters.”
  • 1/2/2018 – GlaxoSmithKline was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $40.00 price target on the stock. According to Zacks, “Glaxo enjoys a diversified base and presence in different geographical areas. Glaxo should continue to see strong performance in its Pharmaceuticals and Vaccines business units. We are positive on the company’s efforts to develop its pipeline. We think Glaxo possesses one of the stronger late-stage pipelines in large-cap pharma. Performance of new products has been encouraging. Meanwhile, back-to-back approvals of three new products – Trelegy Ellipta, Shingrix and Jucalla – have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been impacting the company’s performance. The slowdown in sales of the Consumer Healthcare segment this year is also a concern. However, estimates have gone up slightly ahead of Q4 earnings release. The company has a positive record of earnings surprises in recent quarters.”
  • 12/31/2017 – GlaxoSmithKline was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

GlaxoSmithKline plc (GSK) opened at $36.49 on Monday. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $44.53. The firm has a market capitalization of $90,462.29, a price-to-earnings ratio of 46.19, a price-to-earnings-growth ratio of 2.33 and a beta of 0.98.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The business had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. equities research analysts anticipate that GlaxoSmithKline plc will post 2.82 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be paid a dividend of $0.633 per share. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.94%. GlaxoSmithKline’s dividend payout ratio (DPR) is 258.23%.

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply